Lancet: Risk of cardiovascular events and rofecoxib

Posted by Clark Venable on 11/27/2004

Lancet: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis (pdf)

""Findings: We identified 18 randomised controlled trials and 11 observational studies. By the end of 2000 (52 myocardial infarctions, 20742 patients) the relative risk from randomised controlled trials was 2·30 (95% CI 1·22-4·33, p=0·010), and 1 year later (64 events, 21432 patients) it was 2·24 (1·24-4·02, p=0·007). There was little evidence that the relative risk differed depending on the control group (placebo, non-naproxen NSAID, or naproxen; p=0·41) or trial duration (p=0·82). In observational studies, the cardioprotective effect of naproxen was small (combined estimate 0·86 [95% CI 0·75-0·99]) and could not have explained the findings of the VIGOR trial.""

This post has 0 replies
See full thread

Feeds and Categories

Blog Roll

Google Modules
   Body Mass Index
   Allowable Blood Loss

   The Ether Way
   Westmead Anaesthesia Blog
   Book of Joe
   i'm so sleepy

   Aggravated DocSurg
   Retired Doc
   Finger and Tubes
   Running A Hospital
   Chance To Cut
   DB's Medical Rants
   Palmdoc Chronicles
   The Well-Timed Period


Geeks Like Me
   Seth Dillingham
   Jonathan Greene